Axon Enterprise, Inc $AXON Shares Purchased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC boosted its holdings in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 17.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,877 shares of the biotechnology company's stock after purchasing an additional 571 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Axon Enterprise were worth $3,210,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AXON. Jennison Associates LLC boosted its holdings in Axon Enterprise by 23,203.7% in the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company's stock valued at $322,961,000 after purchasing an additional 611,418 shares in the last quarter. Nuveen LLC acquired a new position in Axon Enterprise in the first quarter valued at approximately $264,796,000. McElhenny Sheffield Capital Management LLC acquired a new position in Axon Enterprise in the second quarter valued at approximately $255,833,000. Westfield Capital Management Co. LP boosted its holdings in Axon Enterprise by 29.8% in the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock valued at $487,977,000 after purchasing an additional 212,931 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Axon Enterprise by 2.2% in the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock valued at $4,540,005,000 after purchasing an additional 185,571 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Axon Enterprise news, CFO Brittany Bagley sold 5,000 shares of the firm's stock in a transaction on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the sale, the chief financial officer owned 93,592 shares of the company's stock, valued at approximately $66,813,456.96. This trade represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Joshua Isner sold 15,919 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the sale, the president directly owned 238,379 shares of the company's stock, valued at approximately $177,892,712.54. This trade represents a 6.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,932 shares of company stock valued at $45,115,616. 5.70% of the stock is currently owned by company insiders.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $704.67 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The stock has a fifty day moving average price of $751.62 and a 200 day moving average price of $715.98. Axon Enterprise, Inc has a 1-year low of $422.38 and a 1-year high of $885.91. The company has a market cap of $55.32 billion, a PE ratio of 173.99, a P/E/G ratio of 27.57 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same period last year, the company earned $1.20 earnings per share. The company's revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AXON. Needham & Company LLC reissued a "buy" rating and issued a $870.00 price objective on shares of Axon Enterprise in a report on Wednesday, September 24th. Raymond James Financial reissued an "outperform" rating and issued a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Northland Securities set a $800.00 price objective on Axon Enterprise in a report on Tuesday, August 5th. Zacks Research downgraded Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Finally, Craig Hallum raised Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price objective for the company in a report on Tuesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.